A report published in Annals of the American Thoracic Society explored the effects of a severe pulmonary illness known as e-cigarette or vaping product use–associated lung injury (EVALI).
“An interdisciplinary group of 26 experts in adult and pediatric clinical care, public health, regulatory oversight, and toxicology were convened for the workshop,” the report reads.
“Four major topics were examined: 1) the public health and regulatory response to EVALI; 2) EVALI clinical care; 3) mechanisms contributing to EVALI; and 4) needed actions to address the health effects of EVALI.”
The workshop established the need for further exploration of the causes of EVALI to prevent future incidences.
“Improving the public health response to reduce the risk of another substantial disease-inducing event depends on coordinated actions to better understand the inhalational toxicity of these products, informing the public of the risks, and developing and enforcing regulatory standards for all e-cigarettes,” according to the report.
